Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageFounded in 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited, AtaiBeckley is a clinical-stage biotechnology company on a mission to create breakthroughs for people with difficult-to-treat mental health conditions. Our work is grounded in rigorous science to deliver meaningful outcomes for the patients we serve. Mental health disorders are highly prevalent and estimated to affect more than one billion people globally.
In the company’s own words · 10-K filed Mar 6, 2026 · SEC EDGAR
Business segments
Jun 2026 · $1.7MThe company’s own SEC segment disclosure.
- Research And Development Services$1.3M74%
- License$437.0K26%
AtaiBeckley Inc. (ATAI) reported revenue of $954K in Q1 2026 (quarter ended Mar 31, 2026). That came with net loss of $30M. For the full year FY2025, revenue was $4.1M (+1228% year on year) and net income −$660M. Its largest product in Jun 2026 was Research And Development Services at $1.3M, 74% of the disclosed total, well ahead of License at 26%.